Viatris VTRS Dymista ® — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viatris in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viatris's dymista ® — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viatris's dymista ® — net sales?
- Viatris (VTRS) reported dymista ® — net sales of $37.3M in Q1 2026.
- How has Viatris's dymista ® — net sales changed year-over-year?
- Viatris's dymista ® — net sales decreased by 12.9% year-over-year, from $42.8M to $37.3M.
- What is the long-term trend for Viatris's dymista ® — net sales?
- Over 4 years (2021 to 2025), Viatris's dymista ® — net sales has grown at a -0.7% compound annual growth rate (CAGR), from $168M to $163.6M.
- What does dymista ® — net sales mean?
- This metric represents the total revenue generated from the sale of the Dymista product line, a specialized nasal spray used for allergic rhinitis. It reflects the market demand and commercial performance of this specific therapeutic asset within the company's broader respiratory and allergy portfolio. Tracking this revenue stream helps investors assess the product's lifecycle stage and its contribution to the company's overall specialty pharmaceutical segment.